Division of General Pediatrics, Department of Pediatrics, Gynecology & Obstetrics, University Hospitals of Geneva and University of Geneva's Faculty of Medicine, Geneva, Switzerland.
Unit of Pediatric Infectious Diseases, Department of Pediatrics, Gynecology & Obstetrics, University Hospitals of Geneva and University of Geneva's Faculty of Medicine, Geneva, Switzerland.
PLoS One. 2023 May 18;18(5):e0285626. doi: 10.1371/journal.pone.0285626. eCollection 2023.
The latest guideline from the American Academy of Pediatrics for the management of bronchiolitis has helped reduce unnecessary interventions and costs. However, data on patients still receiving interventions are missing. In patients with acute bronchiolitis whose management was assessed and compared with current achievable benchmarks of care, we aimed to identify factors associated with nonadherence to guideline recommendations. In this single-centre retrospective study the management of bronchiolitis pre-guideline (Period 1: 2010 to 2012) was compared with two periods post-guideline (Period 2: 2015 to 2016, early post-guideline; and Period 3: 2017 to 2018, late post-guideline) in otherwise healthy infants aged less than 1 year presenting at the Children's University Hospitals of Geneva (Switzerland). Post-guideline, bronchodilators were more frequently administered to older (>6 months; OR 25.8, 95%CI 12.6-52.6), and atopic (OR 3.5, 95%CI 1.5-7.5) children with wheezing (OR 5.4, 95%CI 3.3-8.7). Oral corticosteroids were prescribed more frequently to older (>6 months; OR 5.2, 95%CI 1.4-18.7) infants with wheezing (OR 4.9, 95% CI 1.3-17.8). Antibiotics and chest X-ray were more frequently prescribed to children admitted to the intensive care unit (antibiotics: OR 4.2, 95%CI 1.3-13.5; chest X-ray: OR 19.4, 95%CI 7.4-50.6). Latest prescription rates were all below the achievable benchmarks of care. In summary, following the latest American Academy of Pediatrics guideline, older, atopic children with wheezing and infants admitted to the intensive care unit were more likely to receive nonevidence-based interventions during an episode of bronchiolitis. These patient profiles are generally excluded from bronchiolitis trials, and therefore not specifically covered by the current guideline. Further research should focus on the benefit of bronchiolitis interventions in these particular populations.
美国儿科学会最新的毛细支气管炎管理指南有助于减少不必要的干预措施和成本。然而,关于仍在接受干预措施的患者的数据尚不清楚。在接受管理评估并与当前可实现的护理基准进行比较的急性毛细支气管炎患者中,我们旨在确定与不遵守指南建议相关的因素。在这项单中心回顾性研究中,比较了指南前(第一阶段:2010 年至 2012 年)、指南后(第二阶段:2015 年至 2016 年,早期指南后;第三阶段:2017 年至 2018 年,晚期指南后)毛细支气管炎的管理情况,研究对象为在瑞士日内瓦大学儿童医院就诊的年龄小于 1 岁、 otherwise healthy 的婴儿。在有喘息症状的年长(>6 个月;OR 25.8,95%CI 12.6-52.6)和特应性(OR 3.5,95%CI 1.5-7.5)儿童中,支气管扩张剂的使用更为频繁。在有喘息症状的年长(>6 个月;OR 5.2,95%CI 1.4-18.7)婴儿中,口服皮质类固醇的使用更为频繁。在入住重症监护病房的儿童中,抗生素和胸部 X 光检查更为频繁(抗生素:OR 4.2,95%CI 1.3-13.5;胸部 X 光:OR 19.4,95%CI 7.4-50.6)。最新的处方率均低于可实现的护理基准。总之,在遵循最新的美国儿科学会指南后,患有喘息症状的年长、特应性儿童和入住重症监护病房的婴儿在毛细支气管炎发作期间更有可能接受无证据支持的干预措施。这些患者人群通常被排除在毛细支气管炎试验之外,因此目前的指南并未具体涵盖。进一步的研究应集中在这些特定人群中毛细支气管炎干预措施的益处上。